[Federal Register Volume 77, Number 228 (Tuesday, November 27, 2012)]
[Notices]
[Page 70825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-28662]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Norac

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 31, 2012, Norac, DBA: 
Norac Pharma, 405 S. Motor Avenue, Azusa, California 91702-3232, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
------------------------------------------------------------------------

    With regard to gamma hydroxybutyric acid (2010), 
tetrahydrocannabinols (7370), and methamphetamine (1105) only, the 
company manufactures these controlled substances in bulk solely for 
domestic distribution within the United States to customers engaged in 
dosage-form manufacturing.
    With regard to Nabilone (7379), the company presently manufactures 
a small amount of this controlled substance in bulk solely to conduct 
manufacturing process development internally within the company. It is 
the company's intention that, when the manufacturing process is refined 
to the point that its Nabilone bulk product is available for commercial 
use, the company will export the controlled substance in bulk solely to 
customers engaged in dosage-form manufacturing outside the United 
States. The company is aware of the requirement to obtain a DEA 
registration as an exporter to conduct this activity.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than January 28, 2013.

     Dated: November 19, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-28662 Filed 11-26-12; 8:45 am]
BILLING CODE 4410-09-P